Stock VINC VINCERX PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
0.8771 USD -5.69% Intraday chart for Vincerx Pharma, Inc. +20.15% -25.67%
04-26 Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
04-26 Vincerx Pharma Prices Public Offering of Shares, Warrants MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
AQ
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
AQ
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 
AQ
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
AQ
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
AQ
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
AQ
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Vincerx Pharma To Present Three Posters at ASH 2023 in December
AQ
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
AQ
Vincerx Pharma : Failure to Satisfy Listing Rule - Form 8-K
PU
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
AQ
Vincerx Pharma Announces FDA Clearance of IND for VIP943
AQ
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
Vincerx Pharma : Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Form 8-K
PU
Vincerx Pharma : Modification to Rights of Security Holders - Form 8-K
PU
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
AQ
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
AQ
Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VINC Stock
  4. News Vincerx Pharma, Inc.
  5. Press Releases